`Ph.D.
`26 August 2016
`HarryA.Mar,DICFRNo.7708
`
`Exh. No.:
`1 8
`
`Guidance for Industry
`
`ANDAs: Pharmaceutical
`Solid Polymorphism
`Chemistry, Manufacturing, and Controls Information
`
`U.S. Department of Health and Human Services
`Food and Drug Administration
`Center for Drug Evaluation and Research (CDER)
`July 2007
`OGD
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 1
`
`
`
`Guidance for Industry
`ANDAs: Pharmaceutical
`Solid Polymorphism
`
`Chemistry, Manufacturing, and Controls Information
`
`Additional copies are available from:
`Office of Training and Communication
`Division of Drug Information, HFD-240
`Center for Drug Evaluation and Research
`Food and Drug Administration
`5600 Fishers Lane
`Rockville, MD 20857
`(Tel) 301-827-4573
`http://www.fda.gov/cder/guidance/index
`
`htm
`
`U.S. Department of Health and Human Services
`Food and Drug Administration
`Center for Drug Evaluation and Research (CDER)
`July 2007
`OGD
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 2
`
`
`
`INTRODUCTI ON ..............................................................................................................................................
`I.
`II. DEFINITION OF TERMS: POLYMORPHICFORMS AND POLYMORPHISM...................................2
`GENERAL PRINCIPLES OF PHARMACEUTICALSOLID POLYMORPHISM..............................2
`IH.
`A.
`IMPORTANCE OF PHARMACEUTICALSOLID POLYMORPHISM .........................
`CHARACTERIZATION OF POLYMORPHS................................. ..........................
`B.
`INFLUENCEOF POLYMORPHISM ON DRUG SUBSTANCE AND DRUG PRODUCT.................................................3
`C.
`Influence on Solubility, Dissolution, and Bioavailability (BA) and Bioequivalence (BE)..........................3
`Influence on Manufacturing of the Drug Product
`Influence on Stability......................
`POLYMORPH I SM A ND SA ME NESS I N AND A s
`
`TABLE OF CONTENTS
`
`..........................2
`
`...........................2
`
`1
`
`5
`
`1.
`
`2.
`
`3.
`
`IV.
`
`...................
`
`..
`
`.......
`
`..................4
`
`....
`
`.
`
`...................5
`
`....................................................................................
`
`V. CONSIDERATIONSFOR POLYMORPHISMIN ANDAs..........................................................................6
`A.
`INVESTIGATINGTHE IMPORTANCE OF SETTING SPECIFICATIONS FOR POLYMORPHs ........................................6
`SETTING SPECIFICATIONS FOR POLYMORPHS IN DRUG SUBSTANCES ...............................................................6
`B.
`INVESTIGATINGTHE IMPORTANCE OF SETTING SPECIFICATIONS FORPOLYMORPHS IN DRUG PRODUCTS........7
`C.
`A TTA CHMENT 1
`- DEC I S I ONTREE 1.................................................................................................................
`A TTA CHMENT 2 - DEC I S IONTREE 2 .................................................................................................................
`
`8
`
`9
`
`A TTACHMENT 3 - DEC I S IONTRE E 3 ...............................................................................................................
`
`10
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 3
`
`
`
`Contains nonbinding recommendations
`
`Guidance for Industry'
`
`ANDAs: PharmaceuticalSolid Polymorphism
`Chemistry, Manufacturing, and Controls Information
`
`represents the Food and Drug Administration's (FDA's) current thinking on this topic.
`It
`This guidance,
`does not create or confer any rights for or on any person and does not operate to bind FDA or the public.
`You can use an alternativeapproach if the approach satisfies the requirements of the applicable statutes
`Ifyou want to discuss
`Ifyou
`an alternate approach, contact the appropriateFDA staff
`and regulations.
`cannot identify the appropriateFDA staff call
`the appropriatenumber
`listed on the title page of this
`document.
`
`INTRODUCTION2
`
`I.
`
`Chemistry, manufacturing, and controls (CMC) information must be submitted to support the
`approval of an abbreviated new drug application (ANDA).3 This guidance is intended to assist
`applicants with the submission of ANDAs when a drug substance4 CXiSts in polymorphic forms."
`Specifically, this guidance provides:
`
`(cid:127)
`
`FDA recommendations on assessing sameness6 when the drug substance
`polymorphic forms.
`
`exists in
`
`(cid:127) Decision trees that provide recommendations on monitoring and controlling polymorphs
`in drug substances and/or drug products.
`
`including this guidance, do not establish legally enforceable
`FDA's guidance documents,
`responsibilities.
`Instead, guidances describe the Agency's current thinking on a topic and should
`be viewed only as recommendations, unless specific regulatory or statutory requirements are
`
`i This guidance has been prepared by the Office of Generic Drugs (OGD) in the Office of Pharmaceutical Science
`the Food and Drug Administration (FDA).
`(OPS), Center
`for Drug Evaluation and Research (CDER) at
`2 Although issues relating to polymorphic forms may be relevant to new drug applications (NDAs),
`this guidance
`only addresses polymorphic forms in the context of ANDA approvals.
`see also section 505(j)(4)(A) of the Federal Food, Drug, and Cosmetic Act (the Act).
`3 See 21 CFR 314.94 (a)(9);
`the purposes of this guidance the terms drug substance and active ingredient are used interchangeably.
`4 For
`6 The terms polymorphic forms and polymorphs are synonymous and are used interchangeably in this guidance.
`to Section IV for more information.
`6 Refer
`intended to help industry with the most common types of polymorphs. A drug substance may
`7 This guidance is
`exist in many polymorphic forms, but some forms may be rare and not likely to form.
`For example, in one approved
`in reality only a subset of
`drug product, the drug substance can exist
`twenty polymorphic forms, but
`in at
`least
`polymorphic forms has the potential
`the process conditions used to manufacture the drug substance
`to develop under
`Therefore, we recommend that you consider only those polymorphs that are likely to form during
`and drug product.
`manufacture of the drug substance, manufacture of the drug product, or while the drug substance or drug product
`is
`in storage.
`
`1
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 4
`
`
`
`Contains nonbinding recommendations
`
`cited. The use of the word should in Agency guidances means that something is suggested or
`recommended, but not required.
`
`II.
`
`DEFINITION OF TERMS: POLYMORPHICFORMS AND POLYMORPHISM
`
`We recommend that ANDA applicants investigate whether the drug substance
`in question can
`in polymorphic forms. Polymorphic forms in the context of this guidance refer to
`exist
`crystalline and amorphous forms as well as solvate and hydrate forms, which are described
`below.
`
`(cid:127) Crystalline forms have different arrangementsand/or conformations of the molecules in
`the crystal
`lattice.
`
`(cid:127)
`
`(cid:127)
`
`Amorphous forms consist of disordered arrangementsof molecules that do not possess a
`distinguishable crystal
`lattice.
`
`Solvates are crystal forms containing either stoichiometric or nonstoichiometric amounts
`If the incorporated solvent is water, the solvate is commonly known as a
`of a solvent.
`hydrate.
`
`When a drug substance
`
`exists in polymorphic forms,
`
`it
`
`is said to exhibit polymorphism.
`
`III.
`
`GENERAL PRINCIPLES OF PHARMACEUTICALSOLID POLYMORPHISM
`
`A.
`
`Importance of Pharmaceutical Solid Polymorphism
`
`can have different chemical and physical properties,
`Polymorphic forms of a drug substance
`including melting point, chemical reactivity, apparent solubility,'° dissolution rate, optical and
`mechanical properties, vapor pressure,
`and density. These properties can have a direct effect on
`the ability to process and/or manufacture the drug substance
`and the drug product, as well as on
`drug product stability, dissolution, and bioavailability. Thus, polymorphism can affect the
`quality, safety, and efficacy of the drug product.
`
`B.
`
`Characterization of Polymorphs
`
`There are a number of methods that can be used to characterize polymorphs of a drug
`substance." Demonstration of a nonequivalent structure by single crystalX-ray diffraction is
`
`industry, Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances
`* Guidance for
`and New Drug Products: Chemical Substances,
`International Conference
`on Harmonisation (ICH), December 2000.
`SR Byrn, RR Pfeiffer, and JG Stowell. Solid-State Chemistry ofDrugs.
`2nd Edition, SSCI, Inc., West Lafayette,
`Indiana, 1999.
`10 Apparent solubility refers to the concentration of material at apparent equilibrium (supersaturation). Apparent
`solubility is distinct
`from true thermodynamic solubility, which is reached at
`infinite equilibrium time.
`" H Brittain.
`the characterization of polymorphs and solvates."
`"Methods for
`In HG Brittain (ed.) Polymorphism in
`Pharmaceutical Solids. Marcel Dekker, Inc., New York, 1999, pp. 227-278.
`
`2
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 5
`
`
`
`Contains nonbinding recommendations
`
`currently regarded as the definitive evidence of polymorphism. X-ray powder diffraction can
`also be used to provide unequivocal proof of polymorphism. Other methods, including
`microscopy, thermal analysis (e.g., differential scanning calorimetry, thermal gravimetric
`infrared [IR], Raman, solid-state
`analysis, and hot-stage microscopy), and spectroscopy (e.g.,
`[ssNMR]) are helpful to further characterize polymorphic forms.
`nuclear magnetic resonance
`
`C.
`
`Influence of Polymorphism On Drug Substance And Drug Product
`
`1.
`
`Influence on Solubility, Dissolution, and Bioavailability (BA) and
`Bioequivalence (BE)
`
`The solid-state properties of a drug substance
`can have a significant influence on the apparent
`Since polymorphic forms differ in their internal solid-state
`solubility of the drug substance.
`structure, a drug substance
`that exists in various polymorphic forms can have different aqueous
`solubilities and dissolution rates.12 When there are differences in the apparent solubilities of the
`various polymorphic forms, we recommend that you focus on the potential effect such
`differences can have on drug product bioavailability (BA) and bioequivalence (BE).13
`
`Whether drug product BA/BE can be affected by the differences in apparent solubilities of the
`various polymorphic forms depends on the various physiological
`factors that govern the rate and
`extent of drug absorption including gastrointestinal motility, drug dissolution, and intestinal
`the Biopharmaceutics Classification System (BCS)14, 15 provides a
`permeability.
`In this context,
`useful scientific framework for regulatory decisions regarding drug substance polymorphism.
`
`For a drug whose absorption is only limited by its dissolution, large differences in the apparent
`solubilities of the various polymorphic forms are likely to affect BA/BE. On the other hand, for
`a drug whose absorption is only limited by its intestinal permeability, differences in the apparent
`solubilities of the various polymorphic forms are less likely to affect BA/BE. Furthermore, when
`the apparent solubilities of the polymorphic forms are sufficiently high and drug dissolution is
`rapid in relation to gastric emptying, differences in the solubilities of the polymorphic forms are
`unlikely to affect BA/BE.
`
`"Effect of polymorphism and solid-state solvation on solubility and dissolution rate."
`12 HG Brittain and DJW Grant.
`In HG Brittain (ed.) Polymorphism in Pharmaceutical Solids. Marcel Dekker,
`Inc., New York, 1999,
`pp. 279-330.
`" Bioavailability (BA) is defined in 21 CFR 320.l(a)
`as "the rate and extent to which the active ingredient or active
`moiety is absorbed from a drug product and becomes available at the site of action." Bioequivalence (BE) is
`as "the absence of a significant difference
`defined in 21 CFR 320.l(e)
`in the rate and extent to which the active
`ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the
`site of drug action when administered at the same molar dose under similar conditions in an appropriately designed
`study."
`"A theoretical basis for a biopharmaceutic drug
`14 GL Amidon, H Lennernas, VP Shah, and JR Crison.
`the correlation of in vitro drug product dissolution and in vivobioavailability," Pharm. Res. 12:413-
`classification:
`420, 1995.
`" LX Yu, GL Amidon, JE Polli, H Zhao, M Mehta, DP Conner, VP Shah, LJ Lesko, M-L Chen, VHL Lee, and AS
`"Biopharmaceutics Classification System: The scientific basis for biowaiver extension." Pharm. Res.
`Hussain.
`19:921-925, 2002.
`
`3
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 6
`
`
`
`Contains nonbinding recommendations
`
`Upon demonstration of in-vivo bioequivalence between the generic drug productl6 and the
`reference listed drug (RLD)," in-vitro dissolution testing is then used to assess
`the lot-to-lot
`quality of the generic drug product. Drug product dissolution testing frequently provides a
`suitable means to identify and control the quality of the product from both the bioavailability and
`physical (stability) perspectives. In particular, inadvertent changes to the polymorphic form that
`may affect drug product BA/BE can often be detected by drug product dissolution testing.
`
`2.
`
`Influence on Manufacturing of the Drug Product
`
`Drug substance polymorphic forms can also exhibit different physical and mechanical properties,
`flowability, and compactibility, which in turn
`including hygroscopicity, particle shape, density,
`may affect processing of the drug substance and/or manufacturing of the drug product. Since an
`ANDA applicant should demonstratethat the generic drug product can be manufactured reliably
`using a validated process, we recommend that you pay close attention to polymorphism as it
`relates to pharmaceutical processing.
`
`The effect of polymorphism on pharmaceutical processing also depends on the formulation and
`the manufacturing process." For a drug product manufactured by direct compression, the solid-
`state properties of the active ingredient will
`likely be critical
`to the manufacture of the drug
`product, particularly when it constitutes the bulk of the tablet mass. On the other hand,
`for a
`drug product manufactured by wet granulation, the solid-state properties of the active ingredient
`are often masked by the resultant granulation, and the solid-state properties of the active
`ingredient are less likely to affect the manufacture of the drug product.
`In the context of the
`effect of polymorphism on pharmaceutical processing, what is most
`relevant is the ability to
`consistently manufacture a drug product that conforms to applicable in-process controls and
`release specifications.
`
`Polymorphic forms of the drug substance
`can undergo phase conversion when exposed to a range
`such as drying, milling, micronization, wet granulation, spray-
`of manufacturing processes,
`drying, and compaction. Exposure to environmental conditions such as humidity and
`temperature can also induce polymorph conversion. The extent of conversion generally depends
`on the relative stability of the polymorphs, kinetic barriers to phase conversion, and applied
`stress.20 Nonetheless, phase conversion generally is not of serious concern, provided that the
`conversion occurs consistently, as a part of a validated manufacturing process where critical
`manufacturing process variables are well understood and controlled, and when drug product
`BA/BE has been demonstrated.
`
`refers to a new drug product for which approval
`
`is sought
`
`in an ANDA submitted
`
`16 The term generic drug product
`under section 505(j) of the Act.
`listed drug means the listed drug identified by FDA as the drug
`17 See 21 CFR 314.3 (b) (providing that reference
`product upon which an applicant relies in seeking approval of its abbreviated application).
`* Section 505(j)(4)(A) provides
`that FDA must approve an ANDA if, among other
`things, the methods used in, or
`and packing of the drug are adequate to assure and
`the facilities and controls used for,
`the manufacture, processing,
`preserve its identity, strength, quality, and purity.
`" DA Wadke, ATM Serajuddin, and H Jacobson.
`"Preformulation testing."
`In HA Lieberman, L Lachman, and JB
`(eds.) Pharmaceutical Dosage Forms: Tablets (Vol. 1). Marcel Dekker, Inc., New York, 1989,
`Schwartz
`pp. 1-73.
`20 SR Vippagunta, HG Brittain, DJW Grant.
`
`"Crystalline solids," Adv. Drug Del. Rev. 48:3-26, 2001.
`
`4
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 7
`
`
`
`Contains nonbinding recommendations
`
`3.
`
`Influence on Stability
`
`Polymorphs can have different physical and chemical (reactivity) properties. The most
`thermodynamically stable polymorphic form of a drug substance
`is often chosen during
`development based on the minimal potential for conversion to another polymorphic form and on
`its greater chemical stability. However, a metastable form can be chosen for various reasons,
`including bioavailability enhancement. Since an ANDA applicant must demonstratethat the
`generic drug product exhibits adequatestability,21 we recommend that you focus on the potential
`effect that a polymorphic form can have on drug product stability. Nonetheless, because drug
`product stability is affected by a multitude of other factors,
`including formulation, manufacturing
`process, and packaging, it
`is the stability of the drug product and not stability of the drug
`substance polymorphic form that should be the most
`relevant measure of drug quality.
`
`IV.
`
`POLYMORPHISMAND SAMENESSIN ANDAs
`
`Section 505(j)(2) of the Act specifies that an ANDA must contain, among other things,
`information to show that the active ingredient in the generic drug product is the "same as"
`that of
`the RLD. Under section 505(j)(4) of the Act, FDA must approve an ANDA unless the agency
`finds, among other things, that the ANDA contains insufficient
`information to show that the
`active ingredient is the same as that in the RLD. FDA regulations implementing section 505(j)
`of the Act provide that an ANDA is suitable for consideration and approval if the generic drug
`product is the "same as"
`the RLD. Specifically, 21 CFR 314.92(a)(l) provides that the term
`"same as" means, among other things, "identical
`in active ingredient(s)." The drug substance
`in
`in the RLD if it meets
`a generic drug product is considered to be the same as the drug substance
`for identity.22
`the same standards
`
`When a United States Pharmacopeia (USP) monograph exists for a particular drug substance,
`for identity generally refer to the definition (e.g. chemical name, empirical formula,
`standards
`the beginning of the monograph. However, FDA may
`molecular structure, description) at
`that are material to the sameness of a drug substance.23
`prescribe additional standards
`
`Polymorphic forms of a drug substance differ in internal solid-state structure, but not in chemical
`structure. In the context of sameness of active ingredient(s) in the preamble to the 1992 final
`rule, FDA specifically rejected a proposal that would have required an ANDA applicant to show
`that the active ingredient in its generic drug product and the active ingredient in the RLD
`"exhibit the same physical and chemical characteristics, that no additional residues or impurities
`can result from the different manufacture or synthesis process and that the stereochemistry
`characteristics and solid state forms of the drug have not been altered."24 Therefore, differences
`in drug substance polymorphic forms do not render drug substances different active ingredients
`for the purposes of ANDA approvals within the meaning of the Act and FDA regulations.
`
`21 See footnote
`18.
`22 See preamble to the 1992 final rule (57 FR 17958; April 28, 1992).
`23 See footnote
`22.
`24 See footnote
`22.
`
`5
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 8
`
`
`
`Contains nonbinding recommendations
`
`for identity, each ANDA applicant is required to
`In addition to meeting the standards
`demonstrate that, among other things, the drug product exhibits sufficient stability and is
`bioequivalent to the RLD.25 While the polymorphic form can affect drug product stability and
`bioequivalence, these performance characteristics are also dependent on the formulation,
`the
`manufacturing process, and other physicochemical properties (e.g., particle size, moisture) of
`both the drug substance
`and formulation excipients. Using a drug substance polymorphic form
`that is different from that of the RLD may not preclude an ANDA applicant from formulating a
`generic drug product that exhibits bioequivalence and stability, and the drug substance
`in the
`generic drug product need not have the same polymorphic form as the drug substance
`in the
`RLD.
`
`Over the years, FDA has approved a number of ANDAs in which the drug substance
`in the
`generic drug product had a different polymorphic form from the drug substance
`in the respective
`RLD (e.g., warfarin sodium, famotidine, and ranitidine). FDA also has approved some ANDAs
`in which the drug substance
`in the generic drug product differed in solvate or hydrate forms from
`the drug substance
`in the corresponding RLD (e.g., terazosin hydrochloride, ampicillin, and
`cefadroxil).
`
`V.
`
`CONSIDERATIONS FOR POLYMORPHISMIN ANDAs
`
`to 3 provide ANDA applicants with a suggested
`The decision trees shown in Attachments 1
`for evaluating the importance of and approachesto setting specifications for
`process
`polymorphic forms in solid oral drug products and oral suspensions.
`Although the conceptual
`framework adopted by these decision trees is based primarily on the potential for polymorphic
`forms to affect drug product BA/BE, we recommend that you still consider the influence
`polymorphic forms may have on the ability to manufacture the drug product and on the stability
`of the drug product.
`
`The following sections describe each of the decision trees.
`
`Investigating the Importance of Setting Specifications for Polymorphs
`A.
`Decision Tree 1 provides recommendations on when specifications for polymorphic form(s)26
`for the drug substance and/or the drug product may be appropriate. Polymorphs are unlikely to
`have a significant effect on BA/BE when all forms have the same apparent solubilities or all
`forms are highly soluble.
`
`ANDA applicants are expected to have adequateknowledge about drug substance polymorphs.
`Information on polymorphism can come from the scientific literature, patents, compendia, other
`references,or in some cases, polymorph screening.
`
`B.
`
`Setting Specifications for Polymorphs in Drug Substances
`
`25 See 505(j)(4) of the Act and 21 CFR 314.127.
`26 See footnote 7.
`
`6
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 9
`
`
`
`Contains nonbinding recommendations
`
`Decision Tree 2 provides an approach for setting specifications for polymorphs in the drug
`If relevant
`least one form is known to have low solubility based on the BCS.
`substance when at
`and adequate specifications for polymorphs are included in the USP, ANDA applicants may
`adopt these specifications for the drug substance polymorphic form. Otherwise, we recommend
`that a new specification for the drug substance polymorphic form be established.
`
`C.
`
`Investigating the Importance of Setting Specifications for Polymorphs in
`Drug Products
`
`Decision Tree 3 provides an approach when considering whether to set specifications for
`polymorphs in the drug product. Generally, specifications for polymorphs in drug products are
`if the most
`thermodynamically stable polymorphic form is used or if the same
`not necessary
`form is used in an approved product of the same dosage form. However, since manufacturing
`can affect the polymorphic form, we recommend that you use caution if a metastable
`processes
`form is used.
`
`Drug product performance testing (e.g., dissolution testing) can also generally provide adequate
`control of polymorph ratio changes
`that can influence drug product BA/BE for poorly soluble
`In such instances,
`setting specifications for polymorphs in the drug product would
`drugs.
`generally not be considered important for ensuring adequate product performance. Only in rare
`cases would we recommend setting specifications for polymorphic forms in drug products.
`
`7
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 10
`
`
`
`Contains nonbinding recommendations
`
`ATTACHMENT1-DECISIONTREE 1
`
`Decision Tree 1
`
`Investigating whether to set specifications for polymorphs for solid oral
`and suspensiondosage form products.
`
`NO
`
`Polymorphic form specifications in both the drug
`substance and the drug product
`are unnecessary
`
`þ
`
`YES
`
`START
`
`Are there known
`polymorphs
`with different
`apparent
`solubilities?
`
`YES
`
`Are all polymorphs
`highly soluble as
`defined by BCS
`criteria?
`
`NO
`
`Decision Tree 2
`
`*We recommend that you consider only those polymorphs that are likely to form during manufacture of the drug
`substance, manufacture of the drug product, or while the drug substance or drug product
`is in storage.
`See footnote
`7 in this guidance document.
`
`8
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 11
`
`
`
`Contains nonbinding recommendations
`
`ATTACHMENT2 -- DECISION TREE 2
`
`Decision Tree 2
`
`Setting specifications for polymorphs in drug substances
`dosage form products.
`suspension
`
`for solid oral and
`
`START
`
`Is there a
`polymorph
`specification in the
`USP (e.g., melting
`point)?
`
`NO
`
`YES
`
`Is the polymorph
`specification in the
`USP relevant and
`adequate?
`
`NO
`
`Set a new specification for the drug substance
`polymorphic form.
`
`YES
`
`the same specification for the
`Set
`drug substance polymorphic form as
`in the USP.
`
`,,
`Decision Tree 3
`
`B
`
`9
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 12
`
`
`
`Contains nonbinding recommendations
`
`ATTACHMENT3 - DECISION TREE 3
`
`Decision Tree 3
`
`Investigating whether to set specifications for polymorphs in drug
`dosage form products.
`products for solid oral and suspension
`
`START
`
`a
`
`Is there sufficient
`concern that
`polymorph
`specification in the
`drug product be
`established?*
`
`YES
`
`Does drug product
`performance testing
`(e.g., dissolution
`testing) provide
`adequate controls if
`the polymorph ratio
`changes?
`
`NO
`
`NO
`
`YES
`
`Þ
`
`b
`
`A polymorph specification in
`is unnecessary.
`the drug product
`
`a specification for drug
`Set
`product performance testing
`(e.g., dissolution testing) as
`surrogate for polymorph
`in the drug product.
`control
`
`a
`
`a polymorph specification in the drug product
`Set
`using other approaches, such as a solid-state characterization method.**
`
`*In general,
`there may not be a concern if the most thermodynamically
`stable polymorphic form
`is used or the same form is used in a previously approved product of the same dosage form.
`
`**Drug product performance testing (e.g., dissolution testing) can generally provide adequate
`control of polymorph ratio changes for poorly soluble drugs, which may influence drug product
`BA/BE. Only in rare cases would polymorphic form characterization in the drug product
`be
`recommended.
`
`10
`
`IPR2016-00006
`SteadyMed - Exhibit 1026 - Page 13